Cath Eberlein
Impact in
-
- Cancer, Hypoxia, and Metabolism
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 5
- Angiogenesis and VEGF in Cancer 3
- Cancer therapeutics and mechanisms 3
-
- Lung Cancer Treatments and Mutations 5
- Co-authors
- Simon T. Barry (8 shared papers)Margaret H. Veldman-Jones (2 shared papers)Jon Curwen (1 shared paper)Martin Braddock (1 shared paper)Michael G. Rolf (1 shared paper)Darren A.E. Cross (6 shared papers)David M. Robinson (1 shared paper)Molly A. Taylor (1 shared paper)
- Journals
- Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)Annals of Oncology (2 papers)ACS Medicinal Chemistry Letters (1 paper)Angiogenesis (1 paper)
- Partner nations
- United KingdomUnited StatesSingapore
In The Last Decade
Cath Eberlein
17 papers receiving 270 citations
Peers
Comparison fields: 5 of 54
- Oncology 77
- Cancer Research 38
- Molecular Biology 152
- Hematology 23
- Immunology and Allergy 12
Countries citing papers authored by Cath Eberlein
This map shows the geographic impact of Cath Eberlein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cath Eberlein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cath Eberlein more than expected).
Fields of papers citing papers by Cath Eberlein
This network shows the impact of papers produced by Cath Eberlein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cath Eberlein. The network helps show where Cath Eberlein may publish in the future.
Co-authors
The 25 scholars most cited alongside Cath Eberlein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 69 | |
| 2 | 2012 | 47 | |
| 3 | 2016 | 39 | |
| 4 | 2011 | 30 | |
| 5 | 2017 | 20 | |
| 6 | 2024 | 13 | |
| 7 | 2010 | 13 | |
| 8 | 2023 | 12 | |
| 9 | 2024 | 8 | |
| 10 | 2016 | 7 | |
| 11 | 2024 | 5 | |
| 12 | 2025 | 3 | |
| 13 | 2014 | 3 | |
| 14 | 2015 | 2 | |
| 15 | 2020 | 2 | |
| 16 | 2014 | 2 | |
| 17 | 2013 | 1 |
About Cath Eberlein
Cath Eberlein is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 17 papers that have together received 276 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), HER2/EGFR in Cancer Research (4 papers), Angiogenesis and VEGF in Cancer (3 papers), Cancer therapeutics and mechanisms (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Cancer Mechanisms and Therapy (2 papers) and Cell Adhesion Molecules Research (2 papers). The work is most often cited by research in Oncology (77 citations), Cancer Research (38 citations), Molecular Biology (152 citations), Hematology (23 citations) and Immunology and Allergy (12 citations). Cath Eberlein has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Simon T. Barry, Margaret H. Veldman-Jones, Jon Curwen, Martin Braddock, Michael G. Rolf, Darren A.E. Cross, David M. Robinson, Molly A. Taylor, Matthew J. Martin and Susan Ashton. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Annals of Oncology, ACS Medicinal Chemistry Letters and Angiogenesis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.